The best dialysis therapy? Results from an international survey among nephrology professionals

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background. There is little evidence for superior outcome of one dialysis therapy versus another. Still, nephrologists have to prescribe dialysis every day. It is therefore of interest to ascertain the opinion among nephrology professionals regarding which therapy they consider to be the best and to compare this to reality.

Methods. We designed a survey addressing these questions and distributed it at five international dialysis and nephrology congresses during 2007.

Results. Responses were collected from 6595 delegates, 57% physicians and 28% nurses. Peritoneal dialysis (PD) was considered the best initial dialysis therapy for a planned start in a typical patient. The dialysis treatment chosen to be best for long-term use was home/self-care dialysis applied >3 times/week. The best extracorporeal form of dialysis among European respondents was high-volume haemodiafiltration (HDF), while the Asians and Americans gave preference to high-flux haemodialysis (HD). Only 7% preferred low-flux HD. Finally, the respondents were asked what level of evidence they would require to consider one form of dialysis superior to another. The majority wanted hard evidence, i.e. improved survival, to make such a distinction.

Conclusions. The view of nephrology professionals on the value of different dialysis therapies reflects current scientific discussions. They consider PD to be the best initial therapy and frequent application of home/self-care dialysis to be the best long-term therapy. High-flux membranes are strongly preferred for any extracorporeal form of therapy, and HDF seems to be the modality of choice among Europeans. The opinions expressed are far from reality, which we interpret to show that non-medical factors have a strong impact on treatment allocation.

Related collections

Most cited references 13

Record: found
Abstract: found
Article: not found

Predictors of loss of residual renal function among new dialysis patients.

R Wolfe, Sean Orzol, Susan Young … (2000)

Residual renal function (RRF) in end-stage renal disease is clinically important as it contributes to adequacy of dialysis, quality of life, and mortality. This study was conducted to determine the predictors of RRF loss in a national random sample of patients initiating hemodialysis and peritoneal dialysis. The study controlled for baseline variables and included major predictors. The end point was loss of RRF, defined as a urine volume <200 ml/24 h at approximately 1 yr of follow-up. The adjusted odds ratios (AOR) and P values associated with each of the demographic, clinical, laboratory, and treatment parameters were estimated using an "adjusted" univariate analysis. Significant variables (P < 0.05) were included in a multivariate logistic regression model. Predictors of RRF loss were female gender (AOR = 1.45; P < 0.001), non-white race (AOR = 1.57; P = <0.001), prior history of diabetes (AOR = 1.82; P = 0.006), prior history of congestive heart failure (AOR = 1.32; P = 0.03), and time to follow-up (AOR = 1.06 per month; P = 0.03). Patients treated with peritoneal dialysis had a 65% lower risk of RRF loss than those on hemodialysis (AOR = 0.35; P < 0.001). Higher serum calcium (AOR = 0.81 per mg/dl; P = 0.05), use of an angiotensin-converting enzyme inhibitor (AOR = 0.68; P < 0.001). and use of a calcium channel blocker (AOR = 0.77; P = 0.01) were independently associated with decreased risk of RRF loss. The observations of demographic groups at risk and potentially modifiable factors and therapies have generated testable hypotheses regarding therapies that may preserve RRF among end-stage renal disease patients.

0 comments Cited 99 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Mortality risks of peritoneal dialysis and hemodialysis.

Jun Ma, E G Constantini, James P Ebben … (1999)

Studies of outcomes associated with dialysis therapies have yielded conflicting results. Bloembergen et al showed that prevalent patients on continuous ambulatory peritoneal dialysis (CAPD) or continuous cycling peritoneal dialysis (CCPD) had a 19% higher mortality risk than hemodialysis patients, and Fenton et al, analyzing Canadian incident patients, found a 27% lower risk. Attempting to reconcile these differences, we evaluated incident Medicare patients (99,048 on hemodialysis, 18,110 on CAPD/CCPD) from 1994 through 1996, following up to June 30, 1997. Patients were followed to transplantation, death, loss to follow-up, 60 days after modality change, or end of the study period. For each 3-month survival period, we used an interval Poisson regression to compare death rates, adjusting for age, gender, race, and primary renal diagnosis. A Cox regression was used to evaluate cause-specific mortality, and proportionality was addressed in both regressions by separating diabetic and nondiabetic patients. The Poisson regressions showed CAPD/CCPD to have outcomes comparable with or significantly better than hemodialysis, although results varied over time. The Cox regression found a lower mortality risk in nondiabetic CAPD/CCPD patients (women younger than 55 years: risk ratio [RR] = 0. 61; Cl, 0.59 to 0.66; women age 55 years or older: RR = 0.87; Cl, 0. 84 to 0.91; men younger than 55 years: RR = 0.72; Cl, 0.67 to 0.77; men age 55 years or older: RR = 0.87; Cl, 0.83 to 0.92) and in diabetic CAPD/CCPD patients younger than 55 (women: RR = 0.88; Cl, 0. 82 to 0.94; men: RR = 0.86; Cl, 0.81 to 0.92). The risk of all-cause death for female diabetics 55 years of age and older, in contrast, was 1.21 (Cl, 1.17 to 1.24) for CAPD/CCPD, and in cause-specific analyses, these patients had a significantly higher risk of infectious death. We conclude that, overall, within the first 2 years of therapy, short-term CAPD/CCPD appears to be associated with superior outcomes compared with hemodialysis. It also appears that patients on the two therapies have different mortality patterns over time, a nonproportionality that makes survival analyses vulnerable to the length of follow-up. Further investigation is needed to evaluate both the potential explanations for these findings and the use of more advanced statistical methods in the analysis of mortality rates associated with these dialytic therapies.

0 comments Cited 48 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Daily hemodialysis: a systematic review.

Gihad E Nesrallah, Rajesh R Mainra, Timothy Lindsay … (2005)

Several studies have reported improved outcomes with daily hemodialysis (DHD), but the strength of this evidence has not been evaluated. The published evidence on DHD was synthesized and its quality rated to inform need and sample size calculations for a randomized trial. Citations were identified in MEDLINE and EMBASE using validated search strategies. Dialysis journals that were not indexed and bibliographies of relevant articles were hand-searched. Two authors reviewed all citations. Articles that reported original data on five or more adults who were receiving DHD (1.5 to 3 h, 5 to 7 d/wk) for > or = 3 mo were included. Twenty-five articles reporting 14 unique populations with 268 patients (five to 72 per study) met inclusion criteria. Of the 14 cohorts, 13 were studied with an observational design, 10 were studied prospectively, and four had parallel control groups. Mean age ranged form 41 to 64 yr, mean time on dialysis was 2 to 11 yr, 0 to 28% of patients had diabetes, > 90% had arteriovenous fistulae, and > 50% were dialyzed at home. Most data were described at < or = 12 mo of follow-up. Outcomes included quality of life, cardiovascular disease, erythropoiesis, nutritional status, hospitalizations, and vascular access failures. Reporting was too heterogeneous to allow pooling of data. Ten of 11 studies suggested improvements in blood pressure; findings for other outcomes varied. Discontinuation of DHD occurred in 0 to 57% in-center and 0 to 15% home patients. Studies of DHD are limited by small sample size, nonideal control groups, selection and dropout biases, and paucity of data on potential risks. Randomized trials with adequate statistical power are required to establish the efficacy and the safety of DHD.

0 comments Cited 26 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): NDT Plus

Journal ID (publisher-id): NDTPLUS

Journal ID (hwp): ndtplus

Title: NDT Plus

Publisher: Oxford University Press

ISSN (Print): 1753-0784

ISSN (Electronic): 1753-0792

Publication date (Print): December 2008

Publication date (Electronic): 12 September 2008

Publication date PMC-release: 12 September 2008

Volume: 1

Issue: 6

Pages: 403-408

Affiliations

[1 ]Gambro R&D, Lund, Sweden

[2 ]San Bartolo Hospital , Vicenza, Italy

Author notes

Correspondence and offprint requests to: Ingrid Ledebo, Gambro R&D, Box 10101, S-220 10 Lund, Sweden. Tel: +46-46-16-91-76; Fax: +46-46-16-97-77; E-mail: ingrid.ledebo@ 123456gambro.com

Article

Publisher ID: sfn148

DOI: 10.1093/ndtplus/sfn148

PMC ID: 2584228

PubMed ID: 19020670

SO-VID: fdb1a213-b6bf-4168-bfef-c96ef478e8d0

License:

The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

The best dialysis therapy? Results from an international survey among nephrology professionals

Read this article at

Abstract

Related collections

Karger: Nephrology

Most cited references 13

Predictors of loss of residual renal function among new dialysis patients.

Mortality risks of peritoneal dialysis and hemodialysis.

Daily hemodialysis: a systematic review.

Author and article information

Journal

Affiliations

Author notes

Article

History

Categories

Comments

Comment on this article

Similar content 277

Cited by 21

Most referenced authors 216